ANGIODYNAMICS INC
EXHIBIT 10.1 - SETTLEMENT AGREEMENT
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10.htm
<DESCRIPTION>EXHIBIT 10.1 - SETTLEMENT AGREEMENT
<TEXT>
<html>
  <head>
    <title>ex10.htm</title>
<!-- Licensed to: Skadden-->
<!-- Document Created using EDGARizer 4.0.5.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Exhibit
10.1</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 360pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; TEXT-DECORATION: underline">Execution
Form</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif; TEXT-DECORATION: underline">SETTLEMENT
AGREEMENT</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This
Settlement Agreement is entered into as of March 28, 2008, and shall be
effective as of the Effective Date defined hereinafter, by and between Diomed
Inc. (&#8220;Diomed&#8221;), a Delaware corporation having a principal place of business at
One Dundee Park, Suite 5, P.O. Box 97, Andover, Massachusetts (telecopy
978-475-8488) and AngioDynamics, Inc. (&#8220;AngioDynamics&#8221;), a Delaware corporation
having its principal place of business at 603 Queensbury Avenue, Queensbury, New
York 12804 (telecopy 518.798-3625).&#160;&#160;Diomed and AngioDynamics are
referred to herein individually as a &#8220;Party&#8221; and collectively as &#8220;the
Parties.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">W
I T N E S S E T H</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS,
<a name="returnFill">prior to the Petition Date, Diomed filed a Complaint against
AngioDynamics in the United States District Court for the District of
Massachusetts (the &#8220;Court&#8221;), Civil Action No. 04-10019 (the &#8220;Litigation&#8221;)
alleging infringement of U.S. Patent No. 6,398,777 (&#8220;the &#8216;777 patent&#8221;);
and</a></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS,
final judgment (the &#8220;Judgment&#8221;) in favor of Diomed was entered by the Court on
August 3, 2007; and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS,
AngioDynamics filed a notice of appeal (the &#8220;Appeal&#8221;) to the United States Court
of Appeals for the Federal Circuit (&#8220;CAFC&#8221;); and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS,
Hercules Technology Growth Capital Inc. (&#8220;HTGC&#8221;) claims a security interest and
lien in the Judgment; and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>WHEREAS, on March 14, 2008 (the
&#8220;Petition Date&#8221;) Diomed and its parent, Diomed Holdings Inc., each respectively
filed a voluntary petition for relief under chapter 11 to Title 11 </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">of
the United States Code, 11 U.S.C. &#167;&#167; 101 et seq. (the &#8220;Bankruptcy Code&#8221;) in the
United States Bankruptcy Court for the District of Massachusetts (Worchester
Division) (the &#8220;Bankruptcy Court&#8221;) at jointly administered Case No. 08-40749
(the &#8220;Bankruptcy Case&#8221;); and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>WHEREAS, Diomed remains in control of
its business and affairs as a debtor-in-possession pursuant to section 1107 and
1108 of the Bankruptcy Code; and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS,
this Settlement Agreement, subject to approval by the Bankruptcy Court, is
entered into for the purpose of settling and compromising the monetary judgment
awarded during the Litigation,, any post judgment interest thereon, and any
claims for costs Diomed might have against AngioDynamics; and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS,
each Party has relied wholly upon its own judgment, after consultation with
counsel, in entering into this Settlement Agreement;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;WHEREAS,
nothing herein is intended nor shall be construed to have any effect on any
claims or counterclaims in this Litigation or any other litigation between
Diomed and/or AngioDynamics and any entity that is not a Party to this
Agreement;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;NOW,
THEREFORE, in consideration of the mutual covenants and undertakings set forth
herein, the receipt and sufficiency of which are hereby acknowledged, the
Parties agree as follows:</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">1.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">On
the Effective Date, AngioDynamics and Diomed shall send a letter or other
required documents to Federal Insurance Company (&#8220;Federal&#8221;), surety on the
supersedeas bond filed by AngioDynamics in connection with the Appeal, informing
Federal that the Parties have entered into this Agreement, and instructing
Federal to immediately take, from the assets deposited by AngioDynamics with
Federal as security for the supersedeas bond, the sum of seven million dollars
($7,000,000) (the &#8220;Angio Payment&#8221;) and deliver </font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt">&#160;</div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">such
sum in escrow to bankruptcy counsel to Diomed, McGuireWoods LLP (the &#8220;Escrow
Agent&#8221;), to be disbursed to Diomed pursuant to the procedures set forth in
Paragraphs 2 and 3 of this Agreement.&#160;&#160;The Parties agree that all
other funds held by Federal are the sole and exclusive property of AngioDynamics
and shall be returned to AngioDynamics at its direction.&#160;&#160;Diomed will
execute and shall cause HTGC to execute any documents necessary to waive any
claims to all funds held by Federal in excess of the Angio Payment set forth
above and to confirm that all such excess funds shall be returned at
AngioDynamics&#8217; direction.&#160;&#160;In the event that Federal fails to make the
payment described above to the Escrow Agent within three business days of
receipt of the documents requesting such payment, AngioDynamics shall, by close
of business on the very next business day, make the $7,000,000 payment by wire
transfer in immediately available funds to the Escrow Agent in lieu of the
payment from Federal.&#160;&#160;As a condition to such payment by
AngioDynamics, Diomed will deliver to Federal and cause HTGC to deliver to
Federal any documents required relinquishing and waiving any claim to the funds
held by Federal and confirming that such funds shall be released as directed by
AngioDynamics.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">2.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">On
the next business day after the Angio Payment has been placed in escrow with the
Escrow Agent, the Parties shall submit, or cause to be submitted, a joint
request to the CAFC that the CAFC dismiss the Appeal pursuant to Fed. R. App. P.
42.&#160;&#160;The joint request (the &#8220;Joint Request&#8221;) shall be substantially in
the form of Exhibit A to this Agreement.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">3.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Within
two (2) business days after the CAFC dismisses the Appeal pursuant to the Joint
Request , Diomed shall execute and deliver to the Escrow Agent and cause the
Escrow Agent to provide to AngioDynamics a Satisfaction of Judgment (the
&#8220;Satisfaction of Judgment&#8221;) which shall provide that AngioDynamics has satisfied
in full the monetary judgment of the Court entered on August 3, 2007 and is
therefore released from said monetary obligation.&#160;&#160;The Satisfaction of
Judgment shall be substantially in the form of Exhibit B to this
Agreement.&#160;&#160;The Satisfaction of Judgment shall be delivered with a
written release from HTGC of its security interest and lien in the Judgment (the
&#8220;Secured Creditor Release&#8221;).&#160;&#160;The Secured Creditor Release shall be
substantially in the form of Exhibit C to this Agreement.&#160;&#160;After
delivery of the Satisfaction of Judgment and the Secured Creditor Release to
AngioDynamics, the Escrow Agent will be permitted to disburse the Angio Payment
in the amount set forth in the Order of the Bankruptcy Court authorizing and
approving this Agreement.&#160;&#160;Diomed further agrees that, in light of
this Agreement and the payment it is receiving, Diomed is not entitled to
recover any costs from AngioDynamics relating to the Litigation and agrees not
to file a Bill of Costs as to AngioDynamics in either the Court or
CAFC.&#160;&#160;In addition, Diomed will, and will cause HTGC to, execute any
necessary documents to effectuate the formal release of the supersedeas bond
provided by AngioDynamics in connection with the Appeal.&#160;&#160;Nothing
herein or in the Satisfaction of Judgment shall amend, alter, or release
AngioDynamics&#8217; obligations pursuant to the Permanent Injunction entered by the
Court on July 2, 2007.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">4.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">This
Agreement shall be binding upon each Party, its parents, subsidiaries,
affiliates, partners, shareholders, agents, employees, representatives,
successors and assigns.</font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2">&#160;</div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">5.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">For
a period commencing on the Effective Date and running for one hundred eighty
(180) days thereafter, neither Party shall commence any new civil action against
the other Party or its parent or subsidiary entities, on any basis for any
alleged cause of action, whether or not now known, arising from any facts or
circumstances having taken place prior to the date hereof.&#160;&#160;In the
event of any new civil action or reexamination involving the '777 patent, or any
reissued or reexamined version thereof, or any foreign counterpart thereto,
neither Party shall be precluded from raising or litigating any issue that was
or could have been raised in the Litigation and neither Party shall claim that
collateral estoppel, res judicata or any other legal doctrine precludes any such
issue from being raised and litigated.&#160;&#160;Furthermore, no appeal shall
be taken from the Order of the Court dated January 15, 2008 pertaining to
allegations of contempt.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">6.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">The
Effective Date of this Agreement shall be the date upon which all of the
following have occurred:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 75pt; TEXT-INDENT: 30pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">(a)
approval and authorization of this Agreement by the Board of Directors of
Diomed, with notice given by Diomed </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 75pt; TEXT-INDENT: 30pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">to
AngioDynamics; and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 75pt; TEXT-INDENT: 30pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 105pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">(b)
approval and authorization of this Agreement by the Board of Directors of
AngioDynamics, with notice given by AngioDynamics to Diomed; and</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 75pt; TEXT-INDENT: 30pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 105pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">(c)
entry of an order by the Bankruptcy Court in a form and substance satisfactory
to AngioDynamics authorizing and approving this Agreement in accordance with
Federal Rule of Bankruptcy Procedure 9019 and Bankruptcy Code Section
363.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 35pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">If
the Effective Date has not occurred by April 5, 2008, then either Diomed or
AngioDynamics shall have the right to terminate this Agreement by written notice
to the other.&#160;&#160;Notwithstanding the foregoing, Diomed shall use good
faith best efforts to have the Bankruptcy Court consider authorization and
approval of the Agreement on its previously scheduled hearing date of April 2,
2008.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">7.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">With
respect to the owners of any right, title, or interest in or to the &#8216;777 patent
or any foreign counterparts thereto, subject to receipt of the approval of its
Board of Directors referred to in Section 6(a), Diomed hereby represents and
warrants that it has full authority on behalf of all owners to enter into this
Agreement as provided by Paragraph 4.6(b) of the July 11, 2003 License Agreement
between Diomed and Endolaser Associates LLC (which is the only entity that has
any such rights other than Diomed) and to perform its obligations under this
Agreement.&#160;&#160;With respect to inventor and former owner Dr. Robert Min,
Diomed represents and warrants that it has full authority to enter into this
Agreement as provided by Paragraph 5.4(b) of the July 23, 2003 Purchase
Agreement between Diomed and Dr. Min, and to perform its obligations under this
Agreement.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">8.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Subject
to receipt of the approval of its Board of Directors referred to in Section
6(b), AngioDynamics hereby represents and warrants that it has full authority to
enter into this Agreement and to perform its obligations under this
Agreement.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">9.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">This
Agreement shall be governed by and be interpreted under the internal laws of the
Commonwealth of Massachusetts, without regard to conflicts of laws principles,
and the Parties consent to personal jurisdiction in Massachusetts and agree that
all litigation to enforce the terms hereof shall occur in a court of competent
jurisdiction within the federal or state courts of Massachusetts.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">10.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Should
any provision of this Agreement be declared or be determined by any court to be
illegal or invalid, the validity of the remaining parts, terms, or provisions
shall not be affected thereby and the illegal or invalid part, term, or
provision shall be deemed not to be part of this Agreement.</font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2">&#160;</div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">11.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Both
Parties having contributed to the drafting of this Agreement, there shall be no
presumption against either Party in the interpretation of any ambiguities it may
contain.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">12.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">This
Agreement supersedes any prior or contemporaneous communications, whether
written or oral, concerning the terms of this settlement, and it constitutes the
full and complete agreement of the Parties.&#160;&#160;This Agreement shall not
be orally modified in any respect, and can be modified only by the written
agreement of both Parties.</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">13.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">All
notices, requests and demands to or upon the Parties to be effective shall be in
writing (including by telecopy), and, unless otherwise expressly provided
herein, shall be deemed to have been duly given or made when delivered, or one
business day after being deposited in the mail, postage prepaid, or, in the case
of telecopy notice, when received, sent to the address set forth in the first
paragraph of this Agreement (or to such other address as may be hereafter
notified by any Party).</font></div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt; LINE-HEIGHT: 2"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">14.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">This
Agreement may be executed in counterparts and/or by facsimile.&#160;&#160;Any
Party that provides its signature by facsimile shall provide the opposing Party
with an original ink signature within five business days thereafter; however,
this Agreement shall take full effect immediately upon the exchange of the
Parties&#8217; signatures by facsimile.</font></div>
      <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 2; MARGIN-RIGHT: 0pt">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="MARGIN-LEFT: 35pt; TEXT-INDENT: 70pt"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">15.</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 5pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Each
person signing this Agreement represents that he is authorized to sign it on
behalf of the Party for which he purports to sign.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">[Signature
page follows.]</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 40pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">IN
WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed on
its behalf by the signature of its officer affixed below.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">DIOMED,
      INC.</font></div>
              </td>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">ANGIODYNAMICS,
      INC.</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
              <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">By:&#160;&#160;<font style="TEXT-DECORATION: underline">/s/ James A. Wylie,
      Jr.</font></font></div>
              </td>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">By:&#160;&#160;<font style="TEXT-DECORATION: underline">/s/ Eamonn P.
    Hobbs</font></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
              <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">Name:&#160;&#160;<font style="TEXT-DECORATION: underline">James A. Wylie,
    Jr.</font></font></div>
              </td>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">Name:&#160;&#160;<font style="TEXT-DECORATION: underline">Eamonn P.
  Hobbs</font></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
              <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">Title:&#160;&#160;<font style="TEXT-DECORATION: underline">President &amp;
    CEO</font></font></div>
              </td>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">Title:
      <font style="TEXT-DECORATION: underline">President &amp;
      CEO</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
              <td valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: arial">&#160;
    </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">Dated:&#160;&#160;March
      28,&#160;&#160;2008</font></div>
              </td>
              <td align="left" valign="top" width="40%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif">Dated:
      March 28, 2008</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Cell_Ins" /><a name="Cell_Del" /><a name="Cell_Move" /><a name="Cell_Merge" /><a name="Cell_Pad"><br></a></div>
    </div>
  </body>
</html>

</TEXT>
</DOCUMENT>
